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A worryingly increased incidence of thrombotic events has been
reported among patients suffering from COVID-19 despite standard
antithrombotic prophylaxis [1]. This observation came along with more
recent alerts regarding extremely high prevalence of SARS-CoV-2-po-
sitive patients admitted in intensive care units (ICU) failing to achieve
the target inhibition of the activated factor X (anti-Xa): 95–100%
compared to 27% in internal wards [2,3]. These findings can be ex-
plained by several coagulopathy and pro-thrombotic mechanisms in-
duced by SARS-CoV-2 that lead to heparin resistance and decreased
recovery of anti-Xa activity [3–5]. Furthermore, the increased factor
VIII levels induced by the infection proved to be able to alter aPTT
results, so that other authors have prompt hypothesized a better and
promising application of anti-Xa assessment in monitoring the down-
stream heparin activity in COVID-19 [5]. Nevertheless, to date real-life
evidence of any clinical benefit from this approach for COVID-19
management is missing and this laboratory test can be relatively ex-
pensive and not routinely manageable. To support anti-Xa monitoring
in routine clinical management of COVID-19 further questions have to
be addressed. Is heparin effectiveness a matter of doses or timing? Do
we have to target higher anti-Xa ranges compared to those validated in
surgical and standard prophylaxis? Do we have to monitor intensively
anti-Xa levels due to the frequent and different alterations that may
characterize the different phases of SARS-CoV-2 infection?
We have retrospectively collected and reviewed data from SARS-
CoV-2-positive patients admitted to and dead/discharged from our sub-
intensive unit of Infectious Diseases (Amedeo di Savoia hospital,
Torino, Italy) between March–May 2020 to assess whether the appli-
cation of a clinically driven anti-Xa monitoring may have associated
with the disease outcomes: deaths from overall causes, COVID-19-re-
lated deaths and thrombotic events.
All the included patients were treated with low-molecular-weight
heparin (LMWH) doses adjusted for renal function and body weight and
underwent at least one anti-Xa measurement, while further determi-
nations were clinically driven. We have excluded patients with previous
admissions for COVID-19 in other hospitals, thrombotic events pre-
ceding the admission, low platelets count (< 100,000 cells/μL) and
severe renal impairment (eGFR < 30 mL/min). Peak Anti-Xa levels
were assessed through a chromogenic assay (Anti-Xa STA-Liquid;
STAGO, Asnieres-sur-Seine, France) in citrate plasma withdrawn 4 h
post-LMWH administration. Once-daily LMWH (enoxaparin or parna-
parin) was administered at 6 a.m. to allow for the blood sampling
during the morning shift (10 a.m.). Twice daily LMWH (enoxaparin)
was administered at 6 a.m. and 6 p.m. Anti-Xa target values were
0.3–0.7 and 0.7–1.2 IU/mL for prophylactic and therapeutic use, re-
spectively. While our therapeutic target range is in line with the most
commonly suggested in literature [6], the adopted prophylactic target
range slightly differs from the more commonly suggested 0.2–0.5 UI/
mL [6,7]. Since some authors have suggested adopting higher target
values of anti-Xa for LMWH prophylaxis when patients are character-
ized by significantly higher risk of thrombosis [8], we set our prophy-
lactic target range at 0.3–0.7 UI/mL to be safely and certainly above the
lower target limit of 0.2 usually recommended and not to exceed the
threshold of 0.8, that has been linked to increased bleeding risks [6,9].
Nonparametric tests were performed. Data are presented as median
(95% confidence interval).
56 patients were included: 64.3% were male; the median age, BMI
and serum creatinine were 67 years (59–80), 24.5 (21.9–26.5) and
1.0 mg/dL (0.86–1.22), respectively. 12 patients underwent CPAP, 10
refused it and required mask ventilation with reservoir, while the others
were on wall‑oxygen (maximum FiO2 0.6). At admission, 49 patients
(87.5%) were on once-daily prophylactic enoxaparin (44 patients;
median 4000 IU/dose [4000–6000]) or parnaparin (5 patients; median
4000 IU/dose [4000–4000]), while 7 patients (12.5%) were on twice
daily enoxaparin (median 6000 IU/dose [4000–6000]) due to atrial
fibrillation. The median times from COVID-19 onset to LMWH start and
to hospitalisation were 8 (4–11) and 6 days (3–9), respectively. 3 pul-
monary emboli, 1 deep vein thrombosis and 1 retinal vein occlusion
were observed and 9 deaths occurred. Among the latter, 5 were directly
attributable to COVID-19 (1 pulmonary embolus, 3 respiratory failure
due to severe viral pneumonia, 1 hypoxic myocardial infarction); no
major bleeding was observed.
Anti-Xa activity was measured 126 times (38 patients had at least 2
measurements). 52 determinations (41.3%) were out of the target range
(38 below and 14 above). The median first and second anti-Xa levels
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were 0.4 (0.3–0.6) and 0.5 IU/mL (0.3–0.6), respectively. 30 (53.6%)
and 13 patients (34.2%) did not reach the target range at the first
(39.3% below and 14.3% above) and second assessment (28.9% below
and 5.3% above), respectively. LMWH doses were changed 39 times: 34
(87.2%) based on the anti-Xa results, while 5 times due to clinical in-
dications or suspicions. eGFR significantly deteriorated in 8 patients,
but in none this associated with anti-Xa alterations.
Patients with an available anti-Xa assessment within 72 h from
LMWH prescription presented a lower overall mortality (6.4% vs
28.0%, OR 0.18 [0.033–0.95], p 0.031) compared to those tested later.
Having the first anti-Xa measurement within the target range per se was
not associated with none of the outcomes, as well as no association was
observed between absolute LMWH doses and any of the clinical out-
comes. The pragmatic anti-Xa-based approach represented by main-
taining LMWH doses when first anti-Xa result was within the target or
immediately modifying the dose accordingly associated with a lower
risk of subsequent thrombotic events compared to not modifying
LMWH doses due to competing clinical indications or waiting for a
second anti-Xa assessment as confirmation (2.6% vs 23.5%, OR 0.086
[0.009–0.84], p 0.034).
After adjusting for the worst values of the arterial oxygen partial
pressure to fractional inspired oxygen ratio and of IL-6 zenith during
the hospitalisation, for age and for treatments (corticosteroids, anti-
virals and/or immune-modulants), the prompt correction of LMWH
doses according to the first anti-Xa measurement (if needed) in-
dependently associated with a lower risk of COVID-19-related deaths
(aOR 0.040 [0.002–0.90], p 0.043).
In our small sample of SARS-CoV-2-positive patients admitted to our
sub-intensive ward, we have observed a significantly elevated pre-
valence of patients failing to achieve an effective anti-Xa activity
(41.3%); this value sits in between the prevalence previously reported
in ICU and normal wards [2,3], leading to hypothesize a positive cor-
relation between the disease severity and hampered heparin effective-
ness.
Secondly, rather than with the absolute LMWH doses or with single
in-target anti-Xa assessments, we have observed a favourable associa-
tion between immediate changes of LMWH dose, if needed, after re-
peated evaluations of anti-Xa activity and the positive clinical outcomes
related to COVID-19: a lower risk of thrombotic events and of SARS-
CoV-2-related deaths. This approach was based on standard prophy-
lactic LMWH doses adjusted for renal function and body weight and
having a higher prophylactic range as reference target of anti-Xa ac-
tivity: 0.3–0.7 IU/mL instead of 0.2–0.5 IU/mL, which is more com-
monly used in other clinical conditions. These findings represent the
first evidence of a potential clinical usefulness of anti-Xa-based LMWH
use and of a candidate prophylactic target range in COVID-19, sug-
gesting that patients with COVID-19 may undergo LMWH prophylaxis
targeting higher values of anti-Xa levels compared to the traditional
ones. If confirmed, the data may endorse the application of this la-
boratory tool in ICU as well as in general and sub-intensive wards such
as ours.
This is a routine clinical practice snapshot where blood testing and
management were not based on an orderly study protocol and the
sample size limited adjustments for significant variables. Moreover, the
adopted higher prophylactic anti-Xa target range may limit potential
comparisons with future studies and may have led to an overestimation
of the prevalence of patients not in the advisable range.
Randomized studies on larger and different populations are urgently
required to confirm any improvement in LMWH effectiveness provided
by anti-Xa monitoring and to detail its best application in COVID-19
pandemic, possibly assessing the most effective and safest range of anti-
Xa levels to be targeted, as well as the timing of the measurement and
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